云芝胞内糖肽对老年肺炎临床预后的影响

Effects of polystictus glycopeptide on the clinical prognosis of senile pneumonia

目的探讨云芝胞内糖肽对老年肺炎临床预后的影响。方法 73例在镇江市第一人民医院住院的老年肺炎患者随机分为观察组33例和对照组40例。两组患者均给予抗生素等常规治疗,治疗组患者加用云芝胞内糖肽胶囊口服治疗(每次1.0 g,每日3次),疗程10 d。两组治疗前后均检测血常规、外周血C反应蛋白(CRP)和T淋巴细胞亚群以及行X线片检查。结果治疗10 d后,观察组的总有效率显著高于对照组(93.9%vs.72.5%,Fisher确切概率0.029)。云芝胞内糖肽能增加外周血CD4+和CD4+/CD8+比值,降低CD8+,促进血清CRP的降低(P<0.05),并且未见不良反应。结论云芝胞内糖肽能提高老年肺炎患者的疗效、改善其预后。其机制可能与其调节T淋巴细胞亚群的功能、改善细胞免疫状态、减轻炎症反应有关。

Objective To investigate effects of polystictus glycopeptide on the clinical prognosis of senile pneumonia.Methods Seventy three patients with senile pneumonia in our hospital were randomly divided into observation group （33 cases） and control group （40 cases）. Patients of the two groups were treated by antibiotics and other conventional treatment. Patients of the observation group were also treated by taking polystictus glycopeptide capsule （1.0 g each time, 3 times a day）. A course of treatment was 10 days. Routine blood, peripheral blood C-reactive protein （CRP） and T lymphocyte subgroup were detected, and X-ray examination was also performed in the two groups before and after the treatment.Results The total effective rate in the observation group was significantly higher than the control group after the treatment of 10 days （93.9%vs. 72.5%, Fisher＇s exact probability 0.029）. Furthermore, our study also found that the treatment of polystictus glycopeptide increased peripheral blood CD4＋ and CD4＋/CD8＋ ratio, reduced CD8＋, and promoted the decrease of serum CRP （P〈0.05）, while adverse reactions were not observed.ConclusionPolystictus glycopeptide can improve the curative effect of elderly patients with pneumonia, improve their prognosis. The mechanism may be involving its effects on the regulation of the function of T lymphocyte subsets, improvement of the cellular immunity state and the reduction of inflammation reactions.